ILLUMENATE Pivotal Post-Approval Study (PAS)

ProspectIve, Randomized, SingLe-Blind, U.S. MuLti-Center Study to EvalUate TreatMent of Obstructive SupErficial Femoral Artery or Popliteal LesioNs With A Novel PacliTaxel-CoatEd Percutaneous Angioplasty Balloon Pivotal Post-Approval Study

The ILLUMENATE Pivotal PAS is a continued follow-up study which will include 300 subjects from forty-three (43) sites across the United States and Austria previously enrolled in the ILLUMENATE Pivotal pre-market study to evaluate the Stellarex DCB compared to the PTA control device for the treatment of de-novo or post-PTA occluded/stenotic or reoccluded/restenotic (except for in-stent) SFA and/or popliteal arteries.

Study Overview

• Status: Completed
• Conditions: Peripheral Artery Disease
• Intervention / Treatment: Device: Stellarex 0.035" OTW Drug-coated Angioplasty Balloon; Device: EverCross™ 0.035 PTA Balloon Catheter

Detailed Description

The objective of this continued follow-up of ILLUMENATE Pivotal Study subjects is to demonstrate the long term safety and effectiveness of the Stellarex DCB.

Each enrolled subject will be followed for 5 years (60 months) after treatment. A follow-up office visit will occur at 24 and 36 months. A follow-up telephone contact or an optional office visit will occur at 48 and 60 months.

• Study Type: Interventional
• Enrollment (Actual): 300
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Austria
  • Graz, Austria
    • Medical University Graz
  • Vienna, Austria
    • Hanusch Krankenhaus Wien
• United States
  • Arizona
    • Yuma, Arizona, United States, 85364
      • Yuma Regional Medical Center
  • California
    • Fremont, California, United States, 94538
      • Mission Cardiovascular Research Institute
    • Los Angeles, California, United States, 90017
      • Good Samaritan Hospital - Los Angeles
  • Colorado
    • Loveland, Colorado, United States, 80538
      • Medical Center of the Rockies
  • Connecticut
    • New Haven, Connecticut, United States, 06510
      • Yale University School Of Medicine
  • Florida
    • Gainesville, Florida, United States, 32605
      • Cardiovascular Research of North Florida
    • Miami, Florida, United States, 33176
      • Baptist Cardiac and Vascular Institute
    • Pensacola, Florida, United States, 32504
      • Coastal Vascular and Interventional
  • Georgia
    • Atlanta, Georgia, United States, 30322
      • Emory University Hospital
    • Atlanta, Georgia, United States, 30342
      • Northside Hospital
  • Illinois
    • Oakbrook Terrace, Illinois, United States, 60181
      • Advocate Health and Hospitals Corporation
  • Indiana
    • Fort Wayne, Indiana, United States, 46802
      • St. Joseph Hospital
  • Iowa
    • Des Moines, Iowa, United States, 50309
      • Central Iowa Hospital Corporation
  • Michigan
    • Petoskey, Michigan, United States, 49770
      • Cardiac & Vascular Research Center of Northern Michigan
    • Wyoming, Michigan, United States, 15146
      • Metro Health Hospital
  • Mississippi
    • Jackson, Mississippi, United States, 39216
      • Jackson Heart Clinic
  • New Jersey
    • Browns Mills, New Jersey, United States, 08015
      • Deborah Heart and Lung Center
  • New York
    • New York, New York, United States, 10029
      • Mount Sinai Medical Center
  • North Carolina
    • Asheville, North Carolina, United States, 28801
      • Mission Hospital
    • Raleigh, North Carolina, United States, 27607
      • Rex Hospital
    • Raleigh, North Carolina, United States, 19010
      • Wake Heart Research
  • Ohio
    • Cleveland, Ohio, United States, 44195
      • Cleveland Clinic Foundation
    • Columbus, Ohio, United States, 43214
      • OhioHealth Research Institute
    • Elyria, Ohio, United States, 44035
      • North Ohio Research LTD.
    • Toledo, Ohio, United States, 43606
      • Jobst Vascular Institute
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73120
      • Oklahoma Foundation for Cardiovascular Research
  • Pennsylvania
    • Beaver, Pennsylvania, United States, 15009
      • Heritage Valley Health System
    • Pittsburgh, Pennsylvania, United States, 15232
      • University of Pittsburgh Medical Center
    • Wormleysburg, Pennsylvania, United States, 17043
      • Pinnacle Health Cardiovascular Institute, INC.
  • South Dakota
    • Sioux Falls, South Dakota, United States, 57117
      • Sanford Health Vascular Associates
  • Tennessee
    • Chattanooga, Tennessee, United States, 37403
      • University Surgical Associates
    • Kingsport, Tennessee, United States, 37660
      • Wellmont Holston Valley Medical
    • Knoxville, Tennessee, United States, 37909
      • Premier Surgical Associates
  • Texas
    • Dallas, Texas, United States, 75231
      • Texas Health & Research Education Institution
    • El Paso, Texas, United States, 79902
      • El Paso Cardiology Associates
    • Houston, Texas, United States, 77030
      • University of Texas Health Science Center - Houston
  • Virginia
    • Charlottesville, Virginia, United States, 22908
      • University of Virginia
  • West Virginia
    • Charleston, West Virginia, United States, 25304
      • CAMC Clinical Trial Center
  • Wisconsin
    • Milwaukee, Wisconsin, United States, 53215
      • Aurora Health Care

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria - From ILLUMENATE Pivotal IDE population TP-1397E

Study subjects must fulfill the following clinical criteria:

1. Symptomatic leg ischemia, requiring treatment of the superficial femoral artery (SFA) and/or popliteal artery.
2. Greater than or equal to 18 years of age.
3. Willing to provide written informed consent, and capable and willing to comply with all required follow-up evaluations within the defined follow-up visit windows.
4. Will not undergo other planned vascular interventions within 14 days before and/or 30 days after the protocol treatment (successful treatment of ipsilateral and contralateral iliac permitted prior to enrollment).
5. Life expectancy >1 year.

6. Rutherford-Becker classification of 2, 3 or 4.

   Study Subjects must fulfill the following angiographic criteria:

7. De novo or restenotic lesion (except for in-stent restenotic lesion) >70% within the SFA and/or popliteal artery in a single limb.
8. Single lesion which is ≥3 cm and ≤18cm in length (by visual estimation). NOTE: Tandem lesions can be treated. A tandem lesion is defined as two distinct lesions with 3 cm or less of healthy vessel separating the two diseased areas. The total cumulative length of the tandem lesions, including the healthy vessel, must not exceed 18 cm.
9. Lesion is treatable by no more than two (2) study devices.
10. Successful wire crossing of the lesion. The guidewire advancement should not be indicative of the presence of fresh thrombus in the lesion.
11. Target reference vessel diameter is ≥4 mm and ≤6 mm (by visual estimation).
12. Inflow artery is patent, free from significant lesion stenosis (≥50% stenosis is considered significant) as confirmed by angiography. Treatment of a target lesion is acceptable after successful treatment of inflow artery lesion(s). NOTE: Successful inflow artery treatment is defined as attainment of residual diameter stenosis <30% without death or major vascular complication.
13. Target limb with at least one patent (less than 50% stenosis) tibio-peroneal run-off vessel confirmed by baseline angiography or prior magnetic resonance (MR) angiography or computed tomography (CT) angiography (within 45 days prior to index procedure). NOTE: treatment of outflow disease is NOT permitted.

Exclusion Criteria -

Subject with any of the following clinical criteria should be excluded:

1. Females who are pregnant, lactating, or intend to become pregnant, or males who intend to father children during study participation.
2. Known aortic aneurysm(s) > 5 cm.
3. Contraindication to dual anti-platelet therapy.
4. Known intolerance to study medications, paclitaxel or contrast agents that in the opinion of the investigator cannot be adequately pre-treated.
5. Current participation in an investigational drug or another device study.
6. History of hemorrhagic stroke within 3 months.
7. Previous or planned surgical or interventional procedure within 14 days before or 30 days after the index procedure (successful treatment of ipsilateral and contralateral iliac permitted prior to enrollment).
8. Prior endovascular treatment of target lesion by percutaneous transluminal angioplasty or any other means of previous endovascular treatment (e.g. stents/stent grafts, cutting balloon, scoring balloon, cryoplasty, thrombectomy, atherectomy, brachytherapy or laser devices) within six months of the index procedure, or any previous placement of a bypass graft proximal to the target lesion.
9. Treatment of lesions in the contralateral limb with the CVI Paclitaxel-coated PTA Catheter.
10. Use of the CVI Paclitaxel-coated PTA Catheter in other than a single treatment session.

11. Chronic renal insufficiency (dialysis dependent, or serum creatinine >2.5 mg/dL within 30 days of index procedure).

    Subject with any of the following angiographic criteria should be excluded:

12. Significant contralateral or ipsilateral common femoral disease that requires intervention during the index procedure.
13. No normal proximal arterial segment of the target vessel in which duplex ultrasound velocity ratios can be measured.
14. Known inadequate distal outflow.
15. Acute or sub-acute thrombus in the target vessel.
16. Aneurysmal target vessel.
17. Use of adjunctive therapies (i.e. laser, atherectomy, cryoplasty, scoring/cutting balloons, brachytherapy) during the index procedure in the target lesion or target vessel.
18. Treatment of the contralateral limb during the same procedure or within 30 days following the study procedure (exclusive of the iliac arteries which can be treated prior to enrollment).
19. Presence of concentric calcification that precludes PTA pre-dilation.
20. Prior stent placement in the target vessel.
21. Residual stenosis of greater than 70%, stent placement or flow-limiting (Grade D or greater) dissection following pre-dilation.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: DCB Subjects; The Stellarex DCB is a commercially available PTA balloon catheter (EverCross™ 0.035" PTA Balloon Catheter, Medtronic, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier. Basic Catheter Specifications; Guidewire: 0.035"; Balloon Length: 40/80/120 mm; Sheath Compatibility: greater than or equal to 6 French; Balloon Diameter: 4/5/6 mm; Shaft length: 135 cm The nominal dose density of paclitaxel on the Stellarex DCB is 2.0 μg/mm2. Indications The Stellarex 0.035" OTW Drug-coated Angioplasty Balloon is indicated for percutaneous transluminal angioplasty (PTA), after appropriate vessel preparation, of de novo or restenotic lesions up to 180 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-6 mm.	Device: Stellarex 0.035" OTW Drug-coated Angioplasty Balloon; The Stellarex 0.035" OTW Drug-coated Angioplasty Balloon is indicated for percutaneous transluminal angioplasty (PTA), after appropriate vessel preparation, of de novo or restenotic lesions up to 180 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-6 mm.
Placebo Comparator: PTA Subjects; The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Medtronic, Plymouth, MN 55441, USA). Basic Catheter Specifications; Guidewire: 0.035"; Balloon Length: 40/80/120 mm; Sheath Compatibility: greater to or equal to 6 French; Balloon Diameter: 4/5/6 mm; Shaft length: 135 cm Indications The EverCross Balloon Catheter is intended to dilate stenosis in the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries, and to treat obstructive lesions of native or synthetic arteriovenous dialysis fistulae. This device is also indicated for stent post-dilation in the peripheral vasculature. For additional information refer to the EverCross Instructions for Use.	Device: EverCross™ 0.035 PTA Balloon Catheter; The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Medtronic, Plymouth, MN 55441, USA).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Target Vessel Patency at 24 Months Post-procedure	Patency is defined as the absence of target lesion restenosis as determined by duplex ultrasound (Peak Systolic Velocity Ratio (PSVR) ≤ 2.5) and freedom from clinically-driven target lesion revascularization.	24 months post-procedure
Number of Participants With Freedom From Device and Procedure Related Death Through 30 Days Post-procedure and Freedom From Target Limb Major Amputation and Clinically-driven Target Lesion Revascularization Through 24 Months Post-procedure	The primary safety outcome is defined as freedom from device and procedure-related death through 30 days post-procedure and freedom from target limb major amputation and clinically-driven target lesion revascularization (CD-TLR) through 24 months post-procedure (defined as 730 ± 45 days, i.e., up to 775 days).	24 months post-procedure

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Major Adverse Event (MAE) Rate at 24 Months Post-procedure, Defined as a Composite Rate of Cardiovascular Death, Target Limb Major Amputation and Clinically-driven Target Lesion Revascularization (TLR)	Major adverse event (MAE) rate at 24 months post-procedure, defined as a composite rate of cardiovascular death, target limb major amputation and clinically-driven target lesion revascularization (TLR).	24 months post-procedure
Major Adverse Event (MAE) Rate at 36 Months Post-procedure, Defined as a Composite Rate of Cardiovascular Death, Target Limb Major Amputation and Clinically-driven Target Lesion Revascularization (TLR)	Major adverse event (MAE) rate at 36 months post-procedure, defined as a composite rate of cardiovascular death, target limb major amputation and clinically-driven target lesion revascularization (TLR).	36 months post-procedure
Major Adverse Event (MAE) Rate at 48 Months Post-procedure, Defined as a Composite Rate of Cardiovascular Death, Target Limb Major Amputation and Clinically-driven Target Lesion Revascularization (TLR)	Major adverse event (MAE) rate at 48 months post-procedure, defined as a composite rate of cardiovascular death, target limb major amputation and clinically-driven target lesion revascularization (TLR).	48 months post-procedure
Major Adverse Event (MAE) Rate at 60 Months Post-procedure, Defined as a Composite Rate of Cardiovascular Death, Target Limb Major Amputation and Clinically-driven Target Lesion Revascularization (TLR)	Major adverse event (MAE) rate at 60 months post-procedure, defined as a composite rate of cardiovascular death, target limb major amputation and clinically-driven target lesion revascularization (TLR).	60 months post-procedure
Rate of Clinically-driven Target Lesion Revascularization	Lesion revascularization occuring in the target lesion deemed clinically driven by the Clinical Events Committee. Clinically-driven target lesion revascularization is a repeat revascularization procedure at the target lesion due to a peak systolic velocity ratio ≥ 2.5 by duplex ultrasound or a percent diameter stenosis >50% by angiography accompanied by worsening of the Rutherford Becker Clinical Category or Ankle Brachial Index that is clearly referable to the target lesion.	24 months post-procedure
Rate of Clinically-driven Target Lesion Revascularization	Lesion revascularization occurring in the target lesion deemed clinically driven by the Clinical Events Committee. Clinically-driven target lesion revascularization is a repeat revascularization procedure at the target lesion due to a peak systolic velocity ratio ≥ 2.5 by duplex ultrasound or a percent diameter stenosis >50% by angiography accompanied by worsening of the Rutherford Becker Clinical Category or Ankle Brachial Index that is clearly referable to the target lesion.	36 months post-procedure
Rate of Clinically-driven Target Lesion Revascularization	Lesion revascularization occuring in the target lesion deemed clinically driven by the Clinical Events Committee. Clinically-driven target lesion revascularization is a repeat revascularization procedure at the target lesion due to a peak systolic velocity ratio ≥ 2.5 by duplex ultrasound or a percent diameter stenosis >50% by angiography accompanied by worsening of the Rutherford Becker Clinical Category or Ankle Brachial Index that is clearly referable to the target lesion.	48 months post-procedure
Rate of Clinically-driven Target Lesion Revascularization	Lesion revascularization occurring in the target lesion deemed clinically driven by the Clinical Events Committee. Clinically-driven target lesion revascularization is a repeat revascularization procedure at the target lesion due to a peak systolic velocity ratio ≥ 2.5 by duplex ultrasound or a percent diameter stenosis >50% by angiography accompanied by worsening of the Rutherford Becker Clinical Category or Ankle Brachial Index that is clearly referable to the target lesion.	60 months post-procedure
Rate of Target Lesion Revascularization	Lesion revascularization occuring in the target lesion deemed clinically driven by the Clinical Events Committee	24 months post-procedure
Rate of Target Lesion Revascularization	Lesion revascularization occuring in the target lesion deemed clinically driven by the Clinical Events Committee	36 months post-procedure
Rate of Target Lesion Revascularization	Lesion revascularization occuring in the target lesion deemed clinically driven by the Clinical Events Committee	48 months post-procedure
Rate of Target Lesion Revascularization	Lesion revascularization occuring in the target lesion deemed clinically driven by the Clinical Events Committee	60 months post-procedure
Rate of Clinically-driven Target Vessel Revascularization	Lesion revascularization occuring in the target vessel deemed clinically driven by the Clinical Events Committee. A clinically-driven target vessel revascularization is a repeat revascularization procedure (percutaneous or surgical) of a lesion in the target vessel, exclusive of the target lesion site. A revascularization of the target vessel is considered clinically-driven if the peak systolic velocity ratio ≥ 2.5 by duplex ultrasound or if angiography shows a percent diameter stenosis >50% and there is worsening of the Rutherford Becker Clinical Category or Ankle-Brachial Index.	24 months post-procedure
Rate of Clinically-driven Target Vessel Revascularization	Lesion revascularization occurring in the target vessel deemed clinically driven by the Clinical Events Committee. A clinically-driven target vessel revascularization is a repeat revascularization procedure (percutaneous or surgical) of a lesion in the target vessel, exclusive of the target lesion site. A revascularization of the target vessel is considered clinically-driven if the peak systolic velocity ratio ≥ 2.5 by duplex ultrasound or if angiography shows a percent diameter stenosis >50% and there is worsening of the Rutherford Becker Clinical Category or Ankle-Brachial Index.	36 months post-procedure
Rate of Clinically-driven Target Vessel Revascularization	Lesion revascularization occurring in the target vessel deemed clinically driven by the Clinical Events Committee. A clinically-driven target vessel revascularization is a repeat revascularization procedure (percutaneous or surgical) of a lesion in the target vessel, exclusive of the target lesion site. A revascularization of the target vessel is considered clinically-driven if the peak systolic velocity ratio ≥ 2.5 by duplex ultrasound or if angiography shows a percent diameter stenosis >50% and there is worsening of the Rutherford Becker Clinical Category or Ankle-Brachial Index.	48 months post-procedure
Rate of Clinically-driven Target Vessel Revascularization	Lesion revascularization occurring in the target vessel deemed clinically driven by the Clinical Events Committee. A clinically-driven target vessel revascularization is a repeat revascularization procedure (percutaneous or surgical) of a lesion in the target vessel, exclusive of the target lesion site. A revascularization of the target vessel is considered clinically-driven if the peak systolic velocity ratio ≥ 2.5 by duplex ultrasound or if angiography shows a percent diameter stenosis >50% and there is worsening of the Rutherford Becker Clinical Category or Ankle-Brachial Index.	60 months post-procedure
Rate of Target Limb Major Amputation	Number of subjects in which a major amputation occurred in the target limb	24 months post-procedure
Rate of Target Limb Major Amputation	Number of subjects in which a major amputation occurred in the target limb	36 months post-procedure
Rate of Target Limb Major Amputation	Number of subjects in which a major amputation occurred in the target limb	48 months post-procedure
Rate of Target Limb Major Amputation	Number of subjects in which a major amputation occurred in the target limb	60 months post-procedure
Mortality Rate	Number of subject who have died during the post-procedure follow up period	24 months post-procedure
Mortality Rate	Number of subject who have died during the post-procedure follow up period	36 months post-procedure
Mortality Rate	Number of subject who have died during the post-procedure follow up period	48 months post-procedure
Mortality Rate	Number of subject who have died during the post-procedure follow up period	60 months post-procedure
Rate of Occurrence of Arterial Thrombosis of the Treated Segment	Rate of occurrence of arterial thrombosis of the treated segment	24 months post-procedure
Rate of Occurrence of Arterial Thrombosis of the Treated Segment	Rate of occurrence of arterial thrombosis of the treated segment	36 months post-procedure
Rate of Occurrence of Arterial Thrombosis of the Treated Segment	Rate of occurrence of arterial thrombosis of the treated segment	48 months post-procedure
Rate of Occurrence of Arterial Thrombosis of the Treated Segment	Rate of occurrence of arterial thrombosis of the treated segment	60 months post-procedure
Patency Rate Defined as the Absence of Target Lesion Restenosis as Determined by Duplex Ultrasound (PSVR ≤ 2.5) and Freedom From Clinically-driven TLR	Patency rate defined as the absence of target lesion restenosis as determined by duplex ultrasound (PSVR ≤ 2.5) and freedom from clinically-driven TLR	24 months post-procedure
Patency Rate Defined as the Absence of Target Lesion Restenosis as Determined by Duplex Ultrasound (PSVR ≤ 2.5) and Freedom From Clinically-driven TLR	Patency rate defined as the absence of target lesion restenosis as determined by duplex ultrasound (PSVR ≤ 2.5) and freedom from clinically-driven TLR	36 months post-procedure
Change in Ankle-brachial Index (ABI) From Pre-procedure	The ankle-brachial index (ABI) is the ratio of the blood pressure at the ankle to the blood pressure in the upper arm (brachium). The normal range for the ankle-brachial index is between 0.90 and 1.30. An index under 0.90 means that blood is having a hard time getting to the legs and feet: 0.41 to 0.90 indicates mild to moderate peripheral artery disease; 0.40 and lower indicates severe disease.	24 months post-procedure
Change in Ankle-brachial Index (ABI) From Pre-procedure	The ankle-brachial index (ABI) is the ratio of the blood pressure at the ankle to the blood pressure in the upper arm (brachium). The normal range for the ankle-brachial index is between 0.90 and 1.30. An index under 0.90 means that blood is having a hard time getting to the legs and feet: 0.41 to 0.90 indicates mild to moderate peripheral artery disease; 0.40 and lower indicates severe disease.	36 months post-procedure
Change in Walking Impairment Questionnaire (WIQ) From Pre-procedure	A disease-specific instrument utilized to characterize walking ability through a questionnaire. It is a measure of patient-perceived walking performance for patients with PAD and/or intermittent claudication	24 months post-procedure
Change in Walking Impairment Questionnaire (WIQ) From Pre-procedure	A disease-specific instrument utilized to characterize walking ability through a questionnaire. It is a measure of patient-perceived walking performance for patients with PAD and/or intermittent claudication	36 months post-procedure
Change in Walking Distance From Pre-procedure	Distance in meters or feet traveled in 6 minutes measured at pre-procedure and at 24 month office visit.	24 months post-procedure
Change in Walking Distance From Pre-procedure	Distance in meters or feet traveled in 6 minutes measured at pre-procedure and at 36 month office visit.	36 months post-procedure
Change in Rutherford-Becker Classification From Pre-procedure	Rutherford-Becker Classification is a classification system of Peripheral Arterial Disease, the higher the number the worse the disease. Category Clinical Description 0-Asymptomatic--no hemodynamically significant occlusive disease Mild claudication Moderate claudication Severe claudication 4*-Ischemic rest pain 5*-Minor tissue loss-nonhealing ulcer, focal gangrene with diffuse pedal ischemia 6*-Major tissue loss-extending above transmetatarsal level, functional foot no longer salvageable *Categories 4, 5, and 6 are also described as critical limb ischemia.	24 months post-procedure
Change in Rutherford-Becker Classification From Pre-procedure	Rutherford-Becker Classification is a classification system of Peripheral Arterial Disease, the higher the number the worse the disease. Category Clinical Description 0-Asymptomatic--no hemodynamically significant occlusive disease Mild claudication Moderate claudication Severe claudication 4*-Ischemic rest pain 5*-Minor tissue loss-nonhealing ulcer, focal gangrene with diffuse pedal ischemia 6*-Major tissue loss-extending above transmetatarsal level, functional foot no longer salvageable *Categories 4, 5, and 6 are also described as critical limb ischemia.	36 months post-procedure
Change in EQ-5D Index From Pre-procedure	EQ-5D is designed for self-completion by subjects and is intended to reflect the health status at the time of completion.	24 months post-procedure
Change in EQ-5D Index From Pre-procedure	EQ-5D is designed for self-completion by subjects and is intended to reflect the health status at the time of completion.	36 months post-procedure
Change in EQ-5D VAS From Pre-procedure	EQ-5D is designed for self-completion by subjects and is intended to reflect the health status at the time of completion	24 months post procedure
Change in EQ-5D VAS From Pre-procedure	EQ-5D is designed for self-completion by subjects and is intended to reflect the health status at the time of completion	36 month post procedure

Collaborators and Investigators

• Sponsor: Spectranetics Corporation
• Investigators: Principal Investigator: Prakash Krishnan, MD, Mount Sinai Health System; Principal Investigator: Sean Lyden, MD, The Cleveland Clinic

Publications and helpful links

General Publications

• Gray WA, Jaff MR, Parikh SA, Ansel GM, Brodmann M, Krishnan P, Razavi MK, Vermassen F, Zeller T, White R, Ouriel K, Adelman MA, Lyden SP. Mortality Assessment of Paclitaxel-Coated Balloons: Patient-Level Meta-Analysis of the ILLUMENATE Clinical Program at 3 Years. Circulation. 2019 Oct;140(14):1145-1155. doi: 10.1161/CIRCULATIONAHA.119.040518. Epub 2019 Sep 30.

Study record dates

Study Major Dates

• Study Start (Actual): June 18, 2013
• Primary Completion (Actual): December 8, 2017
• Study Completion (Actual): October 6, 2020

Study Registration Dates

• First Submitted: January 23, 2018
• First Submitted That Met QC Criteria: January 29, 2018
• First Posted (Actual): February 5, 2018

Study Record Updates

• Last Update Posted (Actual): February 2, 2024
• Last Update Submitted That Met QC Criteria: January 8, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Atherosclerosis; Peripheral Vascular Diseases; Peripheral Arterial Disease
• Other Study ID Numbers: D035940

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes